Skip to Content
BiomedicinesBiomedicines
  • Review
  • Open Access

16 November 2026

48 Pages

Orally Administered Plant-Based Cancer Vaccines: Biological Rationale, Current Evidence, and Translational Barriers

,
,
,
and
1
Department of Molecular Biotechnology and Health Sciences, University of Torino, Piazza Nizza 44b, 10126 Turin, Italy
2
Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126 Turin, Italy
3
Institute for Sustainable Plant Protection (IPSP), National Research Council of Italy (CNR), Strada delle Cacce 73, 10135 Turin, Italy
*
Author to whom correspondence should be addressed.

Abstract

Orally administered plant-based cancer vaccines combine recombinant antigen production, cell-wall-mediated bioencapsulation and mucosal delivery, offering a potentially scalable and non-invasive vaccination platform. However, these technological advantages do not necessarily translate into therapeutic antitumor immunity. Following oral administration, plant-made antigens must survive gastrointestinal transit, reach relevant antigen-presenting cells and undergo effective presentation, including MHC-I cross-presentation, while avoiding intestinal tolerance. These requirements are particularly challenging for self-derived tumor-associated antigens. This review critically examines plant-expression platforms, antigen and glycan engineering, gastrointestinal release, mucosal uptake, immune activation and translational requirements. The evidence is organized in a tiered framework distinguishing plant-contained cancer antigens administered orally from parenterally administered plant-made cancer antigens, plant-based oral vaccines targeting oncogenic or other infectious agents and expression-only studies. Direct evidence remains limited to small preclinical investigations. The only identified study reporting an in vivo tumor outcome provided proof of concept that oral administration of a plant-made cancer antigen delayed tumor outgrowth; however, it used a small prophylactic tumor-challenge design and did not establish an antigen-directed immune mechanism or demonstrate therapeutic efficacy against established disease. Further development will require standardized pharmaceutical formulations, quantitative potency assays, established-tumor models and evidence of cross-presentation, functional tumor-reactive T cells, tumor infiltration and survival benefit. Orally administered plant-based cancer vaccines could be investigated as booster or maintenance components of prespecified combination regimens, particularly in minimal residual disease, but this proposed role and their therapeutic efficacy remain unproven.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.